Revenues surge at Salix; quarterly performance tops Street expectations
Salix
On The Web
Site Search
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
RALEIGH, N.C. – Despite a sharp increase in revenues, Salix Pharmaceuticals (Nasdaq: SLXP) reported a larger third quarter loss than in 2008 on Monday.
However, the company which focuses on gastrointestinal drugs, still beat Wall Street expectations.
Salix revenues jumped 53 percent to $65.7 million with a traveler’s diarrhea drug, Xifaxan, delivering nearly double its 2008 revenues at $43 million.
Still, Salix reported a loss of $7.3 million, or 15 cents per share. Analysts polled by Thomson Reuters expected a 29-cent loss.
Driving up losses were increased costs for sales as well as research and development.
Among the expenses was a $5 million payment for acquisition of U.S. rights to a bioadhesive technology.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
- Redbox-Verizon streaming plan to crowd online video space
E-mail Preferences
The Skinny
- Charlotte's startup efforts pick up steam as more data pours in
- 'Battle in Bay 7' returns - Are you techies ready for some basketball?
- Inside RTP's new angel fund: Founders meeting 'significant' need
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO